PharmEasy's valuation has plummeted by 92%, from $5.6 billion to $456 million, despite raising over $200 million in fresh capital earlier this year.
PharmEasy's financial difficulties intensified following the postponement of an $843 million IPO and reliance on debt financing, including a problematic $300 million loan from Goldman Sachs.
Collection
[
|
...
]